Placebo + GLSI-100
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Aug 11, 2022 → Dec 1, 2026
NCT ID
NCT05232916About Placebo + GLSI-100
Placebo + GLSI-100 is a phase 3 stage product being developed by Greenwich LifeSciences for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05232916. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05232916 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Cancer